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Oesophageal ulceration in HIV-infected patients
D P Epstein, M Locketz
Oesophageal ulceration is a well-recognised manifestation 
of HIV infection. Oesophageal ulcers most often occur 
with advanced immunosuppression but have also been 
described in patients undergoing HIV seroconversion.1 
Ulceration usually occurs in the mid- to lower third of the 
oesophagus and presents with odynophagia, dysphagia and 
spontaneous retrosternal chest pain. Complications such 
as bleeding, stricture, perforation or fistula formation are 
well described. In most series cytomegalovirus (CMV) and 
idiopathic oesophageal ulceration are the most common 
causes; however, a broad differential of infectious, neoplastic 
and other diagnoses must be considered in each patient. In 
some cases more than one cause of ulceration may be present. 
Oesophageal ulceration is responsible for significant morbidity, 
impacts on patient nutrition and ability to adhere to oral 
treatment regimens, and is associated with poor survival.2 
No data exist on the aetiology of oesophageal ulceration in 
South African HIV-infected patients. Oesophageal candidiasis 
is the most common oesophageal disorder, and accepted 
practice is to treat patients with oesophageal symptoms with 
empiric oral azole therapy for 7 - 14 days. It is mandatory that 
upper gastrointestinal endoscopy be performed in patients 
who fail to respond to antifungal therapy. In South Africa 
endoscopy is a limited resource and not readily available to the 
majority of HIV infected patients.
We aimed to identify the causes of oesophageal ulceration in 
our patient population.
Study design
From 1 January 2001 to 31 December 2007, all patients with 
confirmed HIV infection and oesophageal symptoms who were 
referred to the Groote Schuur Hospital Gastrointestinal Clinic 
for diagnostic upper endoscopy were considered eligible. 
Only cases with confirmed endoscopic oesophageal ulceration, 
with biopsy, were selected. Oesophageal ulcer was defined 
as a deep mucosal lesion with undermined edges. Sections 
from each specimen were prepared with haemotoxylin and 
eosin (H&E), periodic acid Schiff/Alcian blue, Grocott and 
Ziehl-Neelsen (ZN) stains and with antibody to CMV (Dako, 
Denmark) and reviewed by ML. TB culture was performed in 
certain cases. Clinical records were reviewed. The University of 
Cape Town (UCT) Faculty of Health Sciences Ethics Committee 
approved the study, which was funded by the Divisions of 
Gastroenterology and Anatomical Pathology, UCT.
Results
Fifty-one patients were seen: 31 (60%) were female and 20 
(40%) were male. Their mean age was 35.5±6.9 years. The 
median time to endoscopy after development of symptoms was 
30 days (range 1 - 365 days). The CD4 count ranged from 1 to 
446 cells/µl, with a median of 26 cells/µl and an interquartile 
range (IQR) of 12 - 48 cells/ul.
Eleven patients (21%) had oral lesions at the time of 
endoscopy, comprising 5 oral candidiasis, 2 herpes simplex 
virus (HSV) ulcers, and 4 oral aphthous ulcers. Oral aphthous 
ulcers were associated with idiopathic oesophageal ulcers in all 
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Objective. To determine the aetiology of oesophageal 
ulceration in HIV-infected patients.
Design. A retrospective clinical, endoscopic and 
histopathological analysis of patients with confirmed HIV 
infection and an oesophageal ulcer diagnosed on endoscopy.
Setting. A tertiary referral, gastrointestinal clinic in Cape 
Town.
Results. Fifty-one patients with HIV infection and oesophageal 
ulceration were seen from January 2001 to December 2007. 
Median CD4 count was 26 cells/µl. Mean age was 35.5 years. 
Sixty per cent of patients were female. Forty-nine per cent of 
oesophageal ulcers were idiopathic while 23% were caused 
by cytomegalovirus infection. The remainder were due to 
miscellaneous causes.
Conclusion. A surprisingly small number of patients with HIV-
associated oesophageal ulceration were seen during the study 
period. This may reflect local referral practices or the fact that 
patients with severe immunosuppression succumb before 
developing oesophageal ulcers. As in other series, idiopathic 
oesophageal ulcers and cytomegalovirus ulcers made up the 
majority of cases. Correct biopsy technique and appropriate 
histological and microbiological investigations are associated 
with improved diagnostic yield in these patients.
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4 cases. Twenty-five patients (48%) had idiopathic oesophageal 
ulceration. Of the remaining ulcers, 12 were caused by CMV 
infection (23%), 3 by Candida (6%), 4 by TB (8%) and 1 by HSV 
(2%). CMV and TB were diagnosed in 1 case. In 7 cases no 
ulcer material was present on histological analysis, reflecting 
inadequate biopsy of the lesion.
Of the 4 patients with a TB oesophageal ulcer, 3 were 
diagnosed on direct smear whereas 1 was smear-negative but 
positive on TB culture.
Barium contrast studies were performed on 10 patients for 
suspected fistulas, and 1 was identified (Fig. 1).
Discussion
In our series, as in others, the most common oesophageal ulcers 
were idiopathic (Fig. 2) and those caused by CMV infection 
(Fig. 3).3,4 In view of the HIV epidemic, it is surprising that so 
few patients were seen at a tertiary referral gastrointestinal 
unit, which could be explained by poor referral practices. The 
latter seems unlikely as we have an open-access endoscopy 
policy for HIV-infected patients and good community 
networks. Our study confirms that oesophageal ulceration 
occurs in patients with severe immunosuppression where 81% 
of patients had a CD4 count ≤100 cells/µl. South African HIV-
positive patients may succumb to TB and other opportunistic 
infections before achieving this degree of immunosuppression.
Fig. 1. Oesophago-bronchial fistula.
Fig. 2. Idiopathic oesophageal ulcer.
Fig. 3. CMV oesophageal ulcer.
ORIGINAL ARTICLES
February 2009, Vol. 99, No. 2  SAMJ
109
Oropharyngeal lesions were seen in 21% of patients with 
oesophageal ulceration but this was only predictive of the 
aetiology of the oesophageal lesion in patients with idiopathic 
ulcers; however, only 16% of our idiopathic ulcer group had a 
simultaneous oral ulcer. Oropharyngeal ulceration was found 
in 11% of 124 HIV-associated oesophageal ulcer patients.5 
We also found oral pathology an insensitive indicator of the 
presence and/or aetiology of oesophageal ulceration.
Tuberculous oesophageal ulceration was identified in 4 (8%) 
cases. In Brazil, 17% of oesophageal ulcers in HIV-positive 
patients were due to TB.6 Because of the high incidence of TB 
in HIV-infected people in South Africa, Ziehl-Neelsen staining 
and TB culture should be performed on all patients.
HSV-induced ulceration of the oesophagus is common 
in transplant patients but less common in HIV-infected 
patients,7 with 1 case in our series. We did not include HSV 
immunostaining but, since the inclusions are easily recognised 
morphologically, this omission was probably not responsible 
for the low number identified.
We had no peptic oesophageal ulceration, neoplastic 
ulceration or pill-associated ulceration. Advanced HIV disease 
is associated with hypochlorhydria, and peptic ulceration is 
unusual in this setting.7
Candida was identified in 3 ulcers (6%), which may represent 
colonisation of an idiopathic ulcer since the organisms were 
seen in the ulcer slough rather than invading tissue.
In 7 cases, biopsy material revealed no features of 
ulceration reflecting inadequate biopsy of the lesion. Wilcox 
and colleagues employed a biopsy technique to obtain large 
mucosal samples in their studies of HIV-related oesophageal 
ulcers.4,8 The ‘turn-and-suction’ technique,9 initially devised 
to obtain larger samples in patients undergoing Barrett’s 
oesophagus surveillance, produces larger mucosal samples 
without complications such as bleeding or perforation.
No standardisation in terms of the number and technique 
of biopsies was evident in our series. The cytopathic effect of 
CMV is most notable in infected endothelial cells found within 
granulation tissue in the ulcer base. By comparison, HSV is 
more likely to involve squamous epithelial cells present in 
biopsies from the ulcer edge.4 Correct biopsy technique and 
sample number is important to establish an accurate diagnosis 
in patients with HIV-related oesophageal ulceration.
Oesophageal ulceration occurs in patients with severe 
immunosuppression, and antiretroviral therapy is the 
cornerstone of therapy. Inducing ulcer healing, preventing 
ulcer recurrence, analgesia and maintaining nutrition are other 
components of therapy.
Treatment options for idiopathic oesophageal ulceration 
include oral, intravenous and intralesional steroids. Systemic 
steroids are effective in symptomatic and endoscopic healing of 
idiopathic ulcers;7,10 however, relapse on withdrawal of therapy 
and the increased risk of opportunistic infections are limiting 
factors. Oral thalidomide is effective in healing idiopathic 
oesophageal ulcers10,11 but is associated with significant side-
effects.12
We commence antiretroviral therapy in all patients with 
oesophageal ulceration who are not already on treatment. 
Identified specific opportunistic infections are treated. 
Nutrition is maintained with an oral puree diet or a liquid 
nutritional supplement. Fine-bore nasogastric tube feeding is 
used for patients unable to maintain nutrition orally. None in 
our series required percutaneous endoscopic gastrostomy tube 
feeding. Oral Mist Morphine is routinely used for analgesia.
Oesophageal ulceration is a debilitating manifestation of 
advanced HIV infection and is most often due to idiopathic 
ulceration or CMV. Endoscopy with adequate biopsy of the 
lesion is the investigation of choice. Appropriate histological 
and microbiological tests, including TB culture, should be 
performed in all cases. Contrast studies should be performed 
if complications such as a bronchial fistula or stricture are 
suspected. Pharmacological intervention should include 
antiretroviral therapy and treatment of the causative 
opportunistic infection, if identified.  In addition pain 
management and maintenance of nutrition are important in 
achieving a successful outcome.
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